Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 19 entries
Sorted by: Best Match Show Resources per page
Baseline subjective memory complaints associate with increased risk of incident dementia: the PREADVISE trial.

The journal of prevention of Alzheimer's disease

Abner EL, Kryscio RJ, Caban-Holt AM, Schmitt FA.
PMID: 26180776
J Prev Alzheimers Dis. 2015 Mar;2(1):11-16. doi: 10.14283/jpad.2015.37.

BACKGROUND: Subjective memory complaints reflect patient-identified deficits in memory and have been linked to increased risk of future dementia in nondemented (including cognitively intact) older adults.OBJECTIVES: To assess the risk of incident dementia during follow-up for participants in the...

Cite
Abner EL, Kryscio RJ, Caban-Holt AM, et al. Baseline subjective memory complaints associate with increased risk of incident dementia: the PREADVISE trial. J Prev Alzheimers Dis. 2015;2(1):11-16doi: 10.14283/jpad.2015.37.
Abner, E. L., Kryscio, R. J., Caban-Holt, A. M., & Schmitt, F. A. (2015). Baseline subjective memory complaints associate with increased risk of incident dementia: the PREADVISE trial. The journal of prevention of Alzheimer's disease, 2(1), 11-16. https://doi.org/10.14283/jpad.2015.37
Abner, E L, et al. "Baseline subjective memory complaints associate with increased risk of incident dementia: the PREADVISE trial." The journal of prevention of Alzheimer's disease vol. 2,1 (2015): 11-16. doi: https://doi.org/10.14283/jpad.2015.37
Abner EL, Kryscio RJ, Caban-Holt AM, Schmitt FA. Baseline subjective memory complaints associate with increased risk of incident dementia: the PREADVISE trial. J Prev Alzheimers Dis. 2015 Mar;2(1):11-16. doi: 10.14283/jpad.2015.37. PMID: 26180776; PMCID: PMC4500536.
Copy Download .nbib Format: NLM
Does Finasteride Affect the Severity of Prostate Cancer? A Causal Sensitivity Analysis.

Journal of the American Statistical Association

Shepherd BE, Redman MW, Ankerst DP.
PMID: 20526381
J Am Stat Assoc. 2008 Dec 01;103(484):1392-1404. doi: 10.1198/016214508000000706.

In 2003 Thompson and colleagues reported that daily use of finasteride reduced the prevalence of prostate cancer by 25% compared to placebo. These results were based on the double-blind randomized Prostate Cancer Prevention Trial (PCPT) which followed 18,882 men...

Cite
Shepherd BE, Redman MW, Ankerst DP. Does Finasteride Affect the Severity of Prostate Cancer? A Causal Sensitivity Analysis. J Am Stat Assoc. 2008;103(484):1392-1404doi: 10.1198/016214508000000706.
Shepherd, B. E., Redman, M. W., & Ankerst, D. P. (2008). Does Finasteride Affect the Severity of Prostate Cancer? A Causal Sensitivity Analysis. Journal of the American Statistical Association, 103(484), 1392-1404. https://doi.org/10.1198/016214508000000706
Shepherd, Bryan E, et al. "Does Finasteride Affect the Severity of Prostate Cancer? A Causal Sensitivity Analysis." Journal of the American Statistical Association vol. 103,484 (2008): 1392-1404. doi: https://doi.org/10.1198/016214508000000706
Shepherd BE, Redman MW, Ankerst DP. Does Finasteride Affect the Severity of Prostate Cancer? A Causal Sensitivity Analysis. J Am Stat Assoc. 2008 Dec 01;103(484):1392-1404. doi: 10.1198/016214508000000706. PMID: 20526381; PMCID: PMC2880822.
Copy Download .nbib Format: NLM
Genetic architectures of proximal and distal colorectal cancer are partly distinct.

Gut

Huyghe JR, Harrison TA, Bien SA, Hampel H, Figueiredo JC, Schmit SL, Conti DV, Chen S, Qu C, Lin Y, Barfield R, Baron JA, Cross AJ, Diergaarde B, Duggan D, Harlid S, Imaz L, Kang HM, Levine DM, Perduca V, Perez-Cornago A, Sakoda LC, Schumacher FR, Slattery ML, Toland AE, van Duijnhoven FJB, Van Guelpen B, Agudo A, Albanes D, Alonso MH, Anderson K, Arnau-Collell C, Arndt V, Banbury BL, Bassik MC, Berndt SI, Bézieau S, Bishop DT, Boehm J, Boeing H, Boutron-Ruault MC, Brenner H, Brezina S, Buch S, Buchanan DD, Burnett-Hartman A, Caan BJ, Campbell PT, Carr PR, Castells A, Castellví-Bel S, Chan AT, Chang-Claude J, Chanock SJ, Curtis KR, de la Chapelle A, Easton DF, English DR, Feskens EJM, Gala M, Gallinger SJ, Gauderman WJ, Giles GG, Goodman PJ, Grady WM, Grove JS, Gsur A, Gunter MJ, Haile RW, Hampe J, Hoffmeister M, Hopper JL, Hsu WL, Huang WY, Hudson TJ, Jenab M, Jenkins MA, Joshi AD, Keku TO, Kooperberg C, Kühn T, Küry S, Le Marchand L, Lejbkowicz F, Li CI, Li L, Lieb W, Lindblom A, Lindor NM, Männistö S, Markowitz SD, Milne RL, Moreno L, Murphy N, Nassir R, Offit K, Ogino S, Panico S, Parfrey PS, Pearlman R, Pharoah PDP, Phipps AI, Platz EA, Potter JD, Prentice RL, Qi L, Raskin L, Rennert G, Rennert HS, Riboli E, Schafmayer C, Schoen RE, Seminara D, Song M, Su YR, Tangen CM, Thibodeau SN, Thomas DC, Trichopoulou A, Ulrich CM, Visvanathan K, Vodicka P, Vodickova L, Vymetalkova V, Weigl K, Weinstein SJ, White E, Wolk A, Woods MO, Wu AH, Abecasis GR, Nickerson DA, Scacheri PC, Kundaje A, Casey G, Gruber SB, Hsu L, Moreno V, Hayes RB, Newcomb PA, Peters U.
PMID: 33632709
Gut. 2021 Jul;70(7):1325-1334. doi: 10.1136/gutjnl-2020-321534. Epub 2021 Feb 25.

OBJECTIVE: An understanding of the etiologic heterogeneity of colorectal cancer (CRC) is critical for improving precision prevention, including individualized screening recommendations and the discovery of novel drug targets and repurposable drug candidates for chemoprevention. Known differences in molecular characteristics...

Cite
Huyghe JR, Harrison TA, Bien SA, et al. Genetic architectures of proximal and distal colorectal cancer are partly distinct. Gut. 2021;70(7):1325-1334doi: 10.1136/gutjnl-2020-321534.
Huyghe, J. R., Harrison, T. A., Bien, S. A., Hampel, H., Figueiredo, J. C., Schmit, S. L., Conti, D. V., Chen, S., Qu, C., Lin, Y., Barfield, R., Baron, J. A., Cross, A. J., Diergaarde, B., Duggan, D., Harlid, S., Imaz, L., Kang, H. M., Levine, D. M., Perduca, V., Perez-Cornago, A., Sakoda, L. C., Schumacher, F. R., Slattery, M. L., Toland, A. E., van Duijnhoven, F. J. B., Van Guelpen, B., Agudo, A., Albanes, D., Alonso, M. H., Anderson, K., Arnau-Collell, C., Arndt, V., Banbury, B. L., Bassik, M. C., Berndt, S. I., Bézieau, S., Bishop, D. T., Boehm, J., Boeing, H., Boutron-Ruault, M. C., Brenner, H., Brezina, S., Buch, S., Buchanan, D. D., Burnett-Hartman, A., Caan, B. J., Campbell, P. T., Carr, P. R., Castells, A., Castellví-Bel, S., Chan, A. T., Chang-Claude, J., Chanock, S. J., Curtis, K. R., de la Chapelle, A., Easton, D. F., English, D. R., Feskens, E. J. M., Gala, M., Gallinger, S. J., Gauderman, W. J., Giles, G. G., Goodman, P. J., Grady, W. M., Grove, J. S., Gsur, A., Gunter, M. J., Haile, R. W., Hampe, J., Hoffmeister, M., Hopper, J. L., Hsu, W. L., Huang, W. Y., Hudson, T. J., Jenab, M., Jenkins, M. A., Joshi, A. D., Keku, T. O., Kooperberg, C., Kühn, T., Küry, S., Le Marchand, L., Lejbkowicz, F., Li, C. I., Li, L., Lieb, W., Lindblom, A., Lindor, N. M., Männistö, S., Markowitz, S. D., Milne, R. L., Moreno, L., Murphy, N., Nassir, R., Offit, K., Ogino, S., Panico, S., Parfrey, P. S., Pearlman, R., Pharoah, P. D. P., Phipps, A. I., Platz, E. A., Potter, J. D., Prentice, R. L., Qi, L., Raskin, L., Rennert, G., Rennert, H. S., Riboli, E., Schafmayer, C., Schoen, R. E., Seminara, D., Song, M., Su, Y. R., Tangen, C. M., Thibodeau, S. N., Thomas, D. C., Trichopoulou, A., Ulrich, C. M., Visvanathan, K., Vodicka, P., Vodickova, L., Vymetalkova, V., Weigl, K., Weinstein, S. J., White, E., Wolk, A., Woods, M. O., Wu, A. H., Abecasis, G. R., Nickerson, D. A., Scacheri, P. C., Kundaje, A., Casey, G., Gruber, S. B., Hsu, L., Moreno, V., Hayes, R. B., Newcomb, P. A., & Peters, U. (2021). Genetic architectures of proximal and distal colorectal cancer are partly distinct. Gut, 70(7), 1325-1334. https://doi.org/10.1136/gutjnl-2020-321534
Huyghe, Jeroen R, et al. "Genetic architectures of proximal and distal colorectal cancer are partly distinct." Gut vol. 70,7 (2021): 1325-1334. doi: https://doi.org/10.1136/gutjnl-2020-321534
Huyghe JR, Harrison TA, Bien SA, Hampel H, Figueiredo JC, Schmit SL, Conti DV, Chen S, Qu C, Lin Y, Barfield R, Baron JA, Cross AJ, Diergaarde B, Duggan D, Harlid S, Imaz L, Kang HM, Levine DM, Perduca V, Perez-Cornago A, Sakoda LC, Schumacher FR, Slattery ML, Toland AE, van Duijnhoven FJB, Van Guelpen B, Agudo A, Albanes D, Alonso MH, Anderson K, Arnau-Collell C, Arndt V, Banbury BL, Bassik MC, Berndt SI, Bézieau S, Bishop DT, Boehm J, Boeing H, Boutron-Ruault MC, Brenner H, Brezina S, Buch S, Buchanan DD, Burnett-Hartman A, Caan BJ, Campbell PT, Carr PR, Castells A, Castellví-Bel S, Chan AT, Chang-Claude J, Chanock SJ, Curtis KR, de la Chapelle A, Easton DF, English DR, Feskens EJM, Gala M, Gallinger SJ, Gauderman WJ, Giles GG, Goodman PJ, Grady WM, Grove JS, Gsur A, Gunter MJ, Haile RW, Hampe J, Hoffmeister M, Hopper JL, Hsu WL, Huang WY, Hudson TJ, Jenab M, Jenkins MA, Joshi AD, Keku TO, Kooperberg C, Kühn T, Küry S, Le Marchand L, Lejbkowicz F, Li CI, Li L, Lieb W, Lindblom A, Lindor NM, Männistö S, Markowitz SD, Milne RL, Moreno L, Murphy N, Nassir R, Offit K, Ogino S, Panico S, Parfrey PS, Pearlman R, Pharoah PDP, Phipps AI, Platz EA, Potter JD, Prentice RL, Qi L, Raskin L, Rennert G, Rennert HS, Riboli E, Schafmayer C, Schoen RE, Seminara D, Song M, Su YR, Tangen CM, Thibodeau SN, Thomas DC, Trichopoulou A, Ulrich CM, Visvanathan K, Vodicka P, Vodickova L, Vymetalkova V, Weigl K, Weinstein SJ, White E, Wolk A, Woods MO, Wu AH, Abecasis GR, Nickerson DA, Scacheri PC, Kundaje A, Casey G, Gruber SB, Hsu L, Moreno V, Hayes RB, Newcomb PA, Peters U. Genetic architectures of proximal and distal colorectal cancer are partly distinct. Gut. 2021 Jul;70(7):1325-1334. doi: 10.1136/gutjnl-2020-321534. Epub 2021 Feb 25. PMID: 33632709; PMCID: PMC8223655.
Copy Download .nbib Format: NLM
Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors.

Journal of the National Cancer Institute

Hershman DL, Neugut AI, Moseley A, Arnold KB, Gralow JR, Henry NL, Hillyer GC, Ramsey SD, Unger JM.
PMID: 33629114
J Natl Cancer Inst. 2021 Aug 02;113(8):989-996. doi: 10.1093/jnci/djab022.

BACKGROUND: Nonadherence to aromatase inhibitors (AIs) is common and increases risk of breast cancer (BC) recurrence. We analyzed factors associated with nonadherence among patients enrolled in S1105, a randomized trial of text messaging.METHODS: At enrollment, patients were required to...

Cite
Hershman DL, Neugut AI, Moseley A, et al. Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors. J Natl Cancer Inst. 2021;113(8):989-996doi: 10.1093/jnci/djab022.
Hershman, D. L., Neugut, A. I., Moseley, A., Arnold, K. B., Gralow, J. R., Henry, N. L., Hillyer, G. C., Ramsey, S. D., & Unger, J. M. (2021). Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors. Journal of the National Cancer Institute, 113(8), 989-996. https://doi.org/10.1093/jnci/djab022
Hershman, Dawn L, et al. "Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors." Journal of the National Cancer Institute vol. 113,8 (2021): 989-996. doi: https://doi.org/10.1093/jnci/djab022
Hershman DL, Neugut AI, Moseley A, Arnold KB, Gralow JR, Henry NL, Hillyer GC, Ramsey SD, Unger JM. Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors. J Natl Cancer Inst. 2021 Aug 02;113(8):989-996. doi: 10.1093/jnci/djab022. PMID: 33629114; PMCID: PMC8328987.
Copy Download .nbib Format: NLM
A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer.

Genome medicine

López de Maturana E, Rodríguez JA, Alonso L, Lao O, Molina-Montes E, Martín-Antoniano IA, Gómez-Rubio P, Lawlor R, Carrato A, Hidalgo M, Iglesias M, Molero X, Löhr M, Michalski C, Perea J, O'Rorke M, Barberà VM, Tardón A, Farré A, Muñoz-Bellvís L, Crnogorac-Jurcevic T, Domínguez-Muñoz E, Gress T, Greenhalf W, Sharp L, Arnes L, Cecchini L, Balsells J, Costello E, Ilzarbe L, Kleeff J, Kong B, Márquez M, Mora J, O'Driscoll D, Scarpa A, Ye W, Yu J, García-Closas M, Kogevinas M, Rothman N, Silverman DT, Albanes D, Arslan AA, Beane-Freeman L, Bracci PM, Brennan P, Bueno-de-Mesquita B, Buring J, Canzian F, Du M, Gallinger S, Gaziano JM, Goodman PJ, Gunter M, LeMarchand L, Li D, Neale RE, Peters U, Petersen GM, Risch HA, Sánchez MJ, Shu XO, Thornquist MD, Visvanathan K, Zheng W, Chanock SJ, Easton D, Wolpin BM, Stolzenberg-Solomon RZ, Klein AP, Amundadottir LT, Marti-Renom MA, Real FX, Malats N.
PMID: 33517887
Genome Med. 2021 Feb 01;13(1):15. doi: 10.1186/s13073-020-00816-4.

BACKGROUND: Pancreatic cancer (PC) is a complex disease in which both non-genetic and genetic factors interplay. To date, 40 GWAS hits have been associated with PC risk in individuals of European descent, explaining 4.1% of the phenotypic variance.METHODS: We...

Cite
López de Maturana E, Rodríguez JA, Alonso L, et al. A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Genome Med. 2021;13(1):15doi: 10.1186/s13073-020-00816-4.
López de Maturana, E., Rodríguez, J. A., Alonso, L., Lao, O., Molina-Montes, E., Martín-Antoniano, I. A., Gómez-Rubio, P., Lawlor, R., Carrato, A., Hidalgo, M., Iglesias, M., Molero, X., Löhr, M., Michalski, C., Perea, J., O'Rorke, M., Barberà, V. M., Tardón, A., Farré, A., Muñoz-Bellvís, L., Crnogorac-Jurcevic, T., Domínguez-Muñoz, E., Gress, T., Greenhalf, W., Sharp, L., Arnes, L., Cecchini, L., Balsells, J., Costello, E., Ilzarbe, L., Kleeff, J., Kong, B., Márquez, M., Mora, J., O'Driscoll, D., Scarpa, A., Ye, W., Yu, J., García-Closas, M., Kogevinas, M., Rothman, N., Silverman, D. T., Albanes, D., Arslan, A. A., Beane-Freeman, L., Bracci, P. M., Brennan, P., Bueno-de-Mesquita, B., Buring, J., Canzian, F., Du, M., Gallinger, S., Gaziano, J. M., Goodman, P. J., Gunter, M., LeMarchand, L., Li, D., Neale, R. E., Peters, U., Petersen, G. M., Risch, H. A., Sánchez, M. J., Shu, X. O., Thornquist, M. D., Visvanathan, K., Zheng, W., Chanock, S. J., Easton, D., Wolpin, B. M., Stolzenberg-Solomon, R. Z., Klein, A. P., Amundadottir, L. T., Marti-Renom, M. A., Real, F. X., & Malats, N. (2021). A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Genome medicine, 13(1), 15. https://doi.org/10.1186/s13073-020-00816-4
López de Maturana, Evangelina, et al. "A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer." Genome medicine vol. 13,1 (2021): 15. doi: https://doi.org/10.1186/s13073-020-00816-4
López de Maturana E, Rodríguez JA, Alonso L, Lao O, Molina-Montes E, Martín-Antoniano IA, Gómez-Rubio P, Lawlor R, Carrato A, Hidalgo M, Iglesias M, Molero X, Löhr M, Michalski C, Perea J, O'Rorke M, Barberà VM, Tardón A, Farré A, Muñoz-Bellvís L, Crnogorac-Jurcevic T, Domínguez-Muñoz E, Gress T, Greenhalf W, Sharp L, Arnes L, Cecchini L, Balsells J, Costello E, Ilzarbe L, Kleeff J, Kong B, Márquez M, Mora J, O'Driscoll D, Scarpa A, Ye W, Yu J, García-Closas M, Kogevinas M, Rothman N, Silverman DT, Albanes D, Arslan AA, Beane-Freeman L, Bracci PM, Brennan P, Bueno-de-Mesquita B, Buring J, Canzian F, Du M, Gallinger S, Gaziano JM, Goodman PJ, Gunter M, LeMarchand L, Li D, Neale RE, Peters U, Petersen GM, Risch HA, Sánchez MJ, Shu XO, Thornquist MD, Visvanathan K, Zheng W, Chanock SJ, Easton D, Wolpin BM, Stolzenberg-Solomon RZ, Klein AP, Amundadottir LT, Marti-Renom MA, Real FX, Malats N. A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Genome Med. 2021 Feb 01;13(1):15. doi: 10.1186/s13073-020-00816-4. PMID: 33517887; PMCID: PMC7849104.
Copy Download .nbib Format: NLM
Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Tang H, Jiang L, Stolzenberg-Solomon RZ, Arslan AA, Beane Freeman LE, Bracci PM, Brennan P, Canzian F, Du M, Gallinger S, Giles GG, Goodman PJ, Kooperberg C, Le Marchand L, Neale RE, Shu XO, Visvanathan K, White E, Zheng W, Albanes D, Andreotti G, Babic A, Bamlet WR, Berndt SI, Blackford A, Bueno-de-Mesquita B, Buring JE, Campa D, Chanock SJ, Childs E, Duell EJ, Fuchs C, Gaziano JM, Goggins M, Hartge P, Hassam MH, Holly EA, Hoover RN, Hung RJ, Kurtz RC, Lee IM, Malats N, Milne RL, Ng K, Oberg AL, Orlow I, Peters U, Porta M, Rabe KG, Rothman N, Scelo G, Sesso HD, Silverman DT, Thompson IM, Tjønneland A, Trichopoulou A, Wactawski-Wende J, Wentzensen N, Wilkens LR, Yu H, Zeleniuch-Jacquotte A, Amundadottir LT, Jacobs EJ, Petersen GM, Wolpin BM, Risch HA, Chatterjee N, Klein AP, Li D, Kraft P, Wei P.
PMID: 32546605
Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1784-1791. doi: 10.1158/1055-9965.EPI-20-0275. Epub 2020 Jun 16.

BACKGROUND: Obesity and diabetes are major modifiable risk factors for pancreatic cancer. Interactions between genetic variants and diabetes/obesity have not previously been comprehensively investigated in pancreatic cancer at the genome-wide level.METHODS: We conducted a gene-environment interaction (GxE) analysis including...

Cite
Tang H, Jiang L, Stolzenberg-Solomon RZ, et al. Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Cancer Epidemiol Biomarkers Prev. 2020;29(9):1784-1791doi: 10.1158/1055-9965.EPI-20-0275.
Tang, H., Jiang, L., Stolzenberg-Solomon, R. Z., Arslan, A. A., Beane Freeman, L. E., Bracci, P. M., Brennan, P., Canzian, F., Du, M., Gallinger, S., Giles, G. G., Goodman, P. J., Kooperberg, C., Le Marchand, L., Neale, R. E., Shu, X. O., Visvanathan, K., White, E., Zheng, W., Albanes, D., Andreotti, G., Babic, A., Bamlet, W. R., Berndt, S. I., Blackford, A., Bueno-de-Mesquita, B., Buring, J. E., Campa, D., Chanock, S. J., Childs, E., Duell, E. J., Fuchs, C., Gaziano, J. M., Goggins, M., Hartge, P., Hassam, M. H., Holly, E. A., Hoover, R. N., Hung, R. J., Kurtz, R. C., Lee, I. M., Malats, N., Milne, R. L., Ng, K., Oberg, A. L., Orlow, I., Peters, U., Porta, M., Rabe, K. G., Rothman, N., Scelo, G., Sesso, H. D., Silverman, D. T., Thompson, I. M., Tjønneland, A., Trichopoulou, A., Wactawski-Wende, J., Wentzensen, N., Wilkens, L. R., Yu, H., Zeleniuch-Jacquotte, A., Amundadottir, L. T., Jacobs, E. J., Petersen, G. M., Wolpin, B. M., Risch, H. A., Chatterjee, N., Klein, A. P., Li, D., Kraft, P., & Wei, P. (2020). Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 29(9), 1784-1791. https://doi.org/10.1158/1055-9965.EPI-20-0275
Tang, Hongwei, et al. "Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 29,9 (2020): 1784-1791. doi: https://doi.org/10.1158/1055-9965.EPI-20-0275
Tang H, Jiang L, Stolzenberg-Solomon RZ, Arslan AA, Beane Freeman LE, Bracci PM, Brennan P, Canzian F, Du M, Gallinger S, Giles GG, Goodman PJ, Kooperberg C, Le Marchand L, Neale RE, Shu XO, Visvanathan K, White E, Zheng W, Albanes D, Andreotti G, Babic A, Bamlet WR, Berndt SI, Blackford A, Bueno-de-Mesquita B, Buring JE, Campa D, Chanock SJ, Childs E, Duell EJ, Fuchs C, Gaziano JM, Goggins M, Hartge P, Hassam MH, Holly EA, Hoover RN, Hung RJ, Kurtz RC, Lee IM, Malats N, Milne RL, Ng K, Oberg AL, Orlow I, Peters U, Porta M, Rabe KG, Rothman N, Scelo G, Sesso HD, Silverman DT, Thompson IM, Tjønneland A, Trichopoulou A, Wactawski-Wende J, Wentzensen N, Wilkens LR, Yu H, Zeleniuch-Jacquotte A, Amundadottir LT, Jacobs EJ, Petersen GM, Wolpin BM, Risch HA, Chatterjee N, Klein AP, Li D, Kraft P, Wei P. Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1784-1791. doi: 10.1158/1055-9965.EPI-20-0275. Epub 2020 Jun 16. PMID: 32546605; PMCID: PMC7483330.
Copy Download .nbib Format: NLM
Association of Serum Carotenoids and Retinoids with Intraprostatic Inflammation in Men without Prostate Cancer or Clinical Indication for Biopsy in the Placebo Arm of the Prostate Cancer Prevention Trial.

Nutrition and cancer

Chadid S, Song X, Schenk JM, Gurel B, Lucia MS, Thompson IM, Neuhouser ML, Goodman PJ, Parnes HL, Lippman SM, Nelson WG, De Marzo AM, Platz EA.
PMID: 33511883
Nutr Cancer. 2021 Jan 29;1-8. doi: 10.1080/01635581.2021.1879879. Epub 2021 Jan 29.

Non-supplemental carotenoids and retinol may potentiate antioxidant and anti-inflammatory mechanisms. Chronic intraprostatic inflammation is linked to prostate carcinogenesis. We investigated the association of circulating carotenoids and retinol with intraprostatic inflammation in benign tissue. We included 235 men from the...

Cite
Chadid S, Song X, Schenk JM, et al. Association of Serum Carotenoids and Retinoids with Intraprostatic Inflammation in Men without Prostate Cancer or Clinical Indication for Biopsy in the Placebo Arm of the Prostate Cancer Prevention Trial. Nutr Cancer. 2021;1-8doi: 10.1080/01635581.2021.1879879.
Chadid, S., Song, X., Schenk, J. M., Gurel, B., Lucia, M. S., Thompson, I. M., Neuhouser, M. L., Goodman, P. J., Parnes, H. L., Lippman, S. M., Nelson, W. G., De Marzo, A. M., & Platz, E. A. (2021). Association of Serum Carotenoids and Retinoids with Intraprostatic Inflammation in Men without Prostate Cancer or Clinical Indication for Biopsy in the Placebo Arm of the Prostate Cancer Prevention Trial. Nutrition and cancer, 1-8. https://doi.org/10.1080/01635581.2021.1879879
Chadid, Susan, et al. "Association of Serum Carotenoids and Retinoids with Intraprostatic Inflammation in Men without Prostate Cancer or Clinical Indication for Biopsy in the Placebo Arm of the Prostate Cancer Prevention Trial." Nutrition and cancer vol. (2021): 1-8. doi: https://doi.org/10.1080/01635581.2021.1879879
Chadid S, Song X, Schenk JM, Gurel B, Lucia MS, Thompson IM, Neuhouser ML, Goodman PJ, Parnes HL, Lippman SM, Nelson WG, De Marzo AM, Platz EA. Association of Serum Carotenoids and Retinoids with Intraprostatic Inflammation in Men without Prostate Cancer or Clinical Indication for Biopsy in the Placebo Arm of the Prostate Cancer Prevention Trial. Nutr Cancer. 2021 Jan 29;1-8. doi: 10.1080/01635581.2021.1879879. Epub 2021 Jan 29. PMID: 33511883; PMCID: PMC8319215.
Copy Download .nbib Format: NLM
A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer.

Genome medicine

López de Maturana E, Rodríguez JA, Alonso L, Lao O, Molina-Montes E, Martín-Antoniano IA, Gómez-Rubio P, Lawlor R, Carrato A, Hidalgo M, Iglesias M, Molero X, Löhr M, Michalski C, Perea J, O'Rorke M, Barberà VM, Tardón A, Farré A, Muñoz-Bellvís L, Crnogorac-Jurcevic T, Domínguez-Muñoz E, Gress T, Greenhalf W, Sharp L, Arnes L, Cecchini L, Balsells J, Costello E, Ilzarbe L, Kleeff J, Kong B, Márquez M, Mora J, O'Driscoll D, Scarpa A, Ye W, Yu J, García-Closas M, Kogevinas M, Rothman N, Silverman DT, Albanes D, Arslan AA, Beane-Freeman L, Bracci PM, Brennan P, Bueno-de-Mesquita B, Buring J, Canzian F, Du M, Gallinger S, Gaziano JM, Goodman PJ, Gunter M, LeMarchand L, Li D, Neale RE, Peters U, Petersen GM, Risch HA, Sánchez MJ, Shu XO, Thornquist MD, Visvanathan K, Zheng W, Chanock SJ, Easton D, Wolpin BM, Stolzenberg-Solomon RZ, Klein AP, Amundadottir LT, Marti-Renom MA, Real FX, Malats N.
PMID: 33517887
Genome Med. 2021 Feb 01;13(1):15. doi: 10.1186/s13073-020-00816-4.

BACKGROUND: Pancreatic cancer (PC) is a complex disease in which both non-genetic and genetic factors interplay. To date, 40 GWAS hits have been associated with PC risk in individuals of European descent, explaining 4.1% of the phenotypic variance.METHODS: We...

Cite
López de Maturana E, Rodríguez JA, Alonso L, et al. A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Genome Med. 2021;13(1):15doi: 10.1186/s13073-020-00816-4.
López de Maturana, E., Rodríguez, J. A., Alonso, L., Lao, O., Molina-Montes, E., Martín-Antoniano, I. A., Gómez-Rubio, P., Lawlor, R., Carrato, A., Hidalgo, M., Iglesias, M., Molero, X., Löhr, M., Michalski, C., Perea, J., O'Rorke, M., Barberà, V. M., Tardón, A., Farré, A., Muñoz-Bellvís, L., Crnogorac-Jurcevic, T., Domínguez-Muñoz, E., Gress, T., Greenhalf, W., Sharp, L., Arnes, L., Cecchini, L., Balsells, J., Costello, E., Ilzarbe, L., Kleeff, J., Kong, B., Márquez, M., Mora, J., O'Driscoll, D., Scarpa, A., Ye, W., Yu, J., García-Closas, M., Kogevinas, M., Rothman, N., Silverman, D. T., Albanes, D., Arslan, A. A., Beane-Freeman, L., Bracci, P. M., Brennan, P., Bueno-de-Mesquita, B., Buring, J., Canzian, F., Du, M., Gallinger, S., Gaziano, J. M., Goodman, P. J., Gunter, M., LeMarchand, L., Li, D., Neale, R. E., Peters, U., Petersen, G. M., Risch, H. A., Sánchez, M. J., Shu, X. O., Thornquist, M. D., Visvanathan, K., Zheng, W., Chanock, S. J., Easton, D., Wolpin, B. M., Stolzenberg-Solomon, R. Z., Klein, A. P., Amundadottir, L. T., Marti-Renom, M. A., Real, F. X., & Malats, N. (2021). A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Genome medicine, 13(1), 15. https://doi.org/10.1186/s13073-020-00816-4
López de Maturana, Evangelina, et al. "A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer." Genome medicine vol. 13,1 (2021): 15. doi: https://doi.org/10.1186/s13073-020-00816-4
López de Maturana E, Rodríguez JA, Alonso L, Lao O, Molina-Montes E, Martín-Antoniano IA, Gómez-Rubio P, Lawlor R, Carrato A, Hidalgo M, Iglesias M, Molero X, Löhr M, Michalski C, Perea J, O'Rorke M, Barberà VM, Tardón A, Farré A, Muñoz-Bellvís L, Crnogorac-Jurcevic T, Domínguez-Muñoz E, Gress T, Greenhalf W, Sharp L, Arnes L, Cecchini L, Balsells J, Costello E, Ilzarbe L, Kleeff J, Kong B, Márquez M, Mora J, O'Driscoll D, Scarpa A, Ye W, Yu J, García-Closas M, Kogevinas M, Rothman N, Silverman DT, Albanes D, Arslan AA, Beane-Freeman L, Bracci PM, Brennan P, Bueno-de-Mesquita B, Buring J, Canzian F, Du M, Gallinger S, Gaziano JM, Goodman PJ, Gunter M, LeMarchand L, Li D, Neale RE, Peters U, Petersen GM, Risch HA, Sánchez MJ, Shu XO, Thornquist MD, Visvanathan K, Zheng W, Chanock SJ, Easton D, Wolpin BM, Stolzenberg-Solomon RZ, Klein AP, Amundadottir LT, Marti-Renom MA, Real FX, Malats N. A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Genome Med. 2021 Feb 01;13(1):15. doi: 10.1186/s13073-020-00816-4. PMID: 33517887; PMCID: PMC7849104.
Copy Download .nbib Format: NLM
Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer.

Prostate cancer and prostatic diseases

Karunamuni RA, Huynh-Le MP, Fan CC, Thompson W, Eeles RA, Kote-Jarai Z, Muir K, Lophatananon A, Schleutker J, Pashayan N, Batra J, Grönberg H, Walsh EI, Turner EL, Lane A, Martin RM, Neal DE, Donovan JL, Hamdy FC, Nordestgaard BG, Tangen CM, MacInnis RJ, Wolk A, Albanes D, Haiman CA, Travis RC, Stanford JL, Mucci LA, West CML, Nielsen SF, Kibel AS, Wiklund F, Cussenot O, Berndt SI, Koutros S, Sørensen KD, Cybulski C, Grindedal EM, Park JY, Ingles SA, Maier C, Hamilton RJ, Rosenstein BS, Vega A, Kogevinas M, Penney KL, Teixeira MR, Brenner H, John EM, Kaneva R, Logothetis CJ, Neuhausen SL, Razack A, Newcomb LF, Gamulin M, Usmani N, Claessens F, Gago-Dominguez M, Townsend PA, Roobol MJ, Zheng W, Mills IG, Andreassen OA, Dale AM, Seibert TM.
PMID: 33420416
Prostate Cancer Prostatic Dis. 2021 Jun;24(2):532-541. doi: 10.1038/s41391-020-00311-2. Epub 2021 Jan 08.

BACKGROUND: Polygenic hazard scores (PHS) can identify individuals with increased risk of prostate cancer. We estimated the benefit of additional SNPs on performance of a previously validated PHS (PHS46).MATERIALS AND METHOD: 180 SNPs, shown to be previously associated with...

Cite
Karunamuni RA, Huynh-Le MP, Fan CC, et al. Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. Prostate Cancer Prostatic Dis. 2021;24(2):532-541doi: 10.1038/s41391-020-00311-2.
Karunamuni, R. A., Huynh-Le, M. P., Fan, C. C., Thompson, W., Eeles, R. A., Kote-Jarai, Z., Muir, K., Lophatananon, A., Schleutker, J., Pashayan, N., Batra, J., Grönberg, H., Walsh, E. I., Turner, E. L., Lane, A., Martin, R. M., Neal, D. E., Donovan, J. L., Hamdy, F. C., Nordestgaard, B. G., Tangen, C. M., MacInnis, R. J., Wolk, A., Albanes, D., Haiman, C. A., Travis, R. C., Stanford, J. L., Mucci, L. A., West, C. M. L., Nielsen, S. F., Kibel, A. S., Wiklund, F., Cussenot, O., Berndt, S. I., Koutros, S., Sørensen, K. D., Cybulski, C., Grindedal, E. M., Park, J. Y., Ingles, S. A., Maier, C., Hamilton, R. J., Rosenstein, B. S., Vega, A., Kogevinas, M., Penney, K. L., Teixeira, M. R., Brenner, H., John, E. M., Kaneva, R., Logothetis, C. J., Neuhausen, S. L., Razack, A., Newcomb, L. F., Gamulin, M., Usmani, N., Claessens, F., Gago-Dominguez, M., Townsend, P. A., Roobol, M. J., Zheng, W., Mills, I. G., Andreassen, O. A., Dale, A. M., Seibert, T. M. (2021). Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. Prostate cancer and prostatic diseases, 24(2), 532-541. https://doi.org/10.1038/s41391-020-00311-2
Karunamuni, Roshan A, et al. "Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer." Prostate cancer and prostatic diseases vol. 24,2 (2021): 532-541. doi: https://doi.org/10.1038/s41391-020-00311-2
Karunamuni RA, Huynh-Le MP, Fan CC, Thompson W, Eeles RA, Kote-Jarai Z, Muir K, Lophatananon A, Schleutker J, Pashayan N, Batra J, Grönberg H, Walsh EI, Turner EL, Lane A, Martin RM, Neal DE, Donovan JL, Hamdy FC, Nordestgaard BG, Tangen CM, MacInnis RJ, Wolk A, Albanes D, Haiman CA, Travis RC, Stanford JL, Mucci LA, West CML, Nielsen SF, Kibel AS, Wiklund F, Cussenot O, Berndt SI, Koutros S, Sørensen KD, Cybulski C, Grindedal EM, Park JY, Ingles SA, Maier C, Hamilton RJ, Rosenstein BS, Vega A, Kogevinas M, Penney KL, Teixeira MR, Brenner H, John EM, Kaneva R, Logothetis CJ, Neuhausen SL, Razack A, Newcomb LF, Gamulin M, Usmani N, Claessens F, Gago-Dominguez M, Townsend PA, Roobol MJ, Zheng W, Mills IG, Andreassen OA, Dale AM, Seibert TM. Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. Prostate Cancer Prostatic Dis. 2021 Jun;24(2):532-541. doi: 10.1038/s41391-020-00311-2. Epub 2021 Jan 08. PMID: 33420416; PMCID: PMC8157993.
Copy Download .nbib Format: NLM
Diabetes mitigates the role of memory complaint in predicting dementia risk: Results from the Prevention of Alzheimer's Disease with Vitamin E and Selenium Study.

The journal of prevention of Alzheimer's disease

Zhang X, Schmitt FA, Caban-Holt AM, Ding X, Kryscio RJ, Abner E.
PMID: 28944218
J Prev Alzheimers Dis. 2017;4(3):143-148. doi: 10.14283/jpad.2017.7. Epub 2017 Mar 07.

BACKGROUND: Subjective memory complaints (SMCs) are associated with increased risk of dementia in older adults, but the role of comorbidities in modifying this risk is unknown.OBJECTIVES: To assess whether comorbidities modify estimated dementia risk based on SMCs.DESIGN: The Prevention...

Cite
Zhang X, Schmitt FA, Caban-Holt AM, et al. Diabetes mitigates the role of memory complaint in predicting dementia risk: Results from the Prevention of Alzheimer's Disease with Vitamin E and Selenium Study. J Prev Alzheimers Dis. 2017;4(3):143-148doi: 10.14283/jpad.2017.7.
Zhang, X., Schmitt, F. A., Caban-Holt, A. M., Ding, X., Kryscio, R. J., & Abner, E. (2017). Diabetes mitigates the role of memory complaint in predicting dementia risk: Results from the Prevention of Alzheimer's Disease with Vitamin E and Selenium Study. The journal of prevention of Alzheimer's disease, 4(3), 143-148. https://doi.org/10.14283/jpad.2017.7
Zhang, X, et al. "Diabetes mitigates the role of memory complaint in predicting dementia risk: Results from the Prevention of Alzheimer's Disease with Vitamin E and Selenium Study." The journal of prevention of Alzheimer's disease vol. 4,3 (2017): 143-148. doi: https://doi.org/10.14283/jpad.2017.7
Zhang X, Schmitt FA, Caban-Holt AM, Ding X, Kryscio RJ, Abner E. Diabetes mitigates the role of memory complaint in predicting dementia risk: Results from the Prevention of Alzheimer's Disease with Vitamin E and Selenium Study. J Prev Alzheimers Dis. 2017;4(3):143-148. doi: 10.14283/jpad.2017.7. Epub 2017 Mar 07. PMID: 28944218; PMCID: PMC5607951.
Copy Download .nbib Format: NLM
Circulating Levels of Testosterone, Sex Hormone Binding Globulin and Colorectal Cancer Risk: Observational and Mendelian Randomization Analyses.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Dimou N, Mori N, Harlid S, Harbs J, Martin RM, Smith-Byrne K, Papadimitriou N, Bishop DT, Casey G, Colorado-Yohar SM, Cotterchio M, Cross AJ, Marchand LL, Lin Y, Offit K, Onland-Moret NC, Peters U, Potter JD, Rohan TE, Weiderpass E, Gunter MJ, Murphy N.
PMID: 33879453
Cancer Epidemiol Biomarkers Prev. 2021 Jul;30(7):1336-1348. doi: 10.1158/1055-9965.EPI-20-1690. Epub 2021 Apr 20.

BACKGROUND: Epidemiologic studies evaluating associations between sex steroid hormones and colorectal cancer risk have yielded inconsistent results. To elucidate the role of circulating levels of testosterone, and sex hormone-binding globulin (SHBG) in colorectal cancer risk, we conducted observational and...

Cite
Dimou N, Mori N, Harlid S, et al. Circulating Levels of Testosterone, Sex Hormone Binding Globulin and Colorectal Cancer Risk: Observational and Mendelian Randomization Analyses. Cancer Epidemiol Biomarkers Prev. 2021;30(7):1336-1348doi: 10.1158/1055-9965.EPI-20-1690.
Dimou, N., Mori, N., Harlid, S., Harbs, J., Martin, R. M., Smith-Byrne, K., Papadimitriou, N., Bishop, D. T., Casey, G., Colorado-Yohar, S. M., Cotterchio, M., Cross, A. J., Marchand, L. L., Lin, Y., Offit, K., Onland-Moret, N. C., Peters, U., Potter, J. D., Rohan, T. E., Weiderpass, E., Gunter, M. J., & Murphy, N. (2021). Circulating Levels of Testosterone, Sex Hormone Binding Globulin and Colorectal Cancer Risk: Observational and Mendelian Randomization Analyses. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 30(7), 1336-1348. https://doi.org/10.1158/1055-9965.EPI-20-1690
Dimou, Niki, et al. "Circulating Levels of Testosterone, Sex Hormone Binding Globulin and Colorectal Cancer Risk: Observational and Mendelian Randomization Analyses." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 30,7 (2021): 1336-1348. doi: https://doi.org/10.1158/1055-9965.EPI-20-1690
Dimou N, Mori N, Harlid S, Harbs J, Martin RM, Smith-Byrne K, Papadimitriou N, Bishop DT, Casey G, Colorado-Yohar SM, Cotterchio M, Cross AJ, Marchand LL, Lin Y, Offit K, Onland-Moret NC, Peters U, Potter JD, Rohan TE, Weiderpass E, Gunter MJ, Murphy N. Circulating Levels of Testosterone, Sex Hormone Binding Globulin and Colorectal Cancer Risk: Observational and Mendelian Randomization Analyses. Cancer Epidemiol Biomarkers Prev. 2021 Jul;30(7):1336-1348. doi: 10.1158/1055-9965.EPI-20-1690. Epub 2021 Apr 20. PMID: 33879453.
Copy Download .nbib Format: NLM
Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement process.

Journal of comparative effectiveness research

Deverka PA, Lavallee DC, Desai PJ, Armstrong J, Gorman M, Hole-Curry L, O'Leary J, Ruffner BW, Watkins J, Veenstra DL, Baker LH, Unger JM, Ramsey SD.
PMID: 23459832
J Comp Eff Res. 2012 Jul;1(4):359-70. doi: 10.2217/cer.12.36.

AIMS: The Center for Comparative Effectiveness Research in Cancer Genomics completed a 2-year stakeholder-guided process for the prioritization of genomic tests for comparative effectiveness research studies. We sought to evaluate the effectiveness of engagement procedures in achieving project goals...

Cite
Deverka PA, Lavallee DC, Desai PJ, et al. Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement process. J Comp Eff Res. 2012;1(4):359-70doi: 10.2217/cer.12.36.
Deverka, P. A., Lavallee, D. C., Desai, P. J., Armstrong, J., Gorman, M., Hole-Curry, L., O'Leary, J., Ruffner, B. W., Watkins, J., Veenstra, D. L., Baker, L. H., Unger, J. M., & Ramsey, S. D. (2012). Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement process. Journal of comparative effectiveness research, 1(4), 359-70. https://doi.org/10.2217/cer.12.36
Deverka, Patricia A, et al. "Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement process." Journal of comparative effectiveness research vol. 1,4 (2012): 359-70. doi: https://doi.org/10.2217/cer.12.36
Deverka PA, Lavallee DC, Desai PJ, Armstrong J, Gorman M, Hole-Curry L, O'Leary J, Ruffner BW, Watkins J, Veenstra DL, Baker LH, Unger JM, Ramsey SD. Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement process. J Comp Eff Res. 2012 Jul;1(4):359-70. doi: 10.2217/cer.12.36. PMID: 23459832; PMCID: PMC3583228.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 19 entries